UK-based private equity company Pamplona Capital Management has agreed to acquire Parexel International Corporation by acquiring the entire outstanding shares of the company in an all-cash transaction.
The purchase consideration for the acquisition has been fixed at $88.1 per share, valuing the transaction at $5bn inclusive of net debt.
Go deeper with GlobalData
The target company is a biopharmaceutical firm based in the US and will become a privately held company following the acquisition, which is expected to be completed by this year's fourth quarter.
Spherix has reached an agreement to acquire a controlling stake in biopharmaceutical company, Hoth Therapeutics.
The acquirer company is a scientific research company also based in the US, and the acquisition is expected to increase Spherix’s shareholder value.
See Also:
Quantum Hi-Tech China Biological has reached an agreement to acquire Shanghai ChemPartner, a contract research organisation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBoth companies involved in the acquisition are based in China. The acquisition is expected to be completed by the end of the year.
